Second Cancer Incidence and Cause‐Specific Mortality in Primary Gastrointestinal Non‐Hodgkin Lymphoma Survivors: A Population‐Based Cohort Study
Cancer Medicine · 2025
DOI: 10.1002/cam4.71405 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Cancer Medicine, 2025. Verfasst von Jiahe Wu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, People's Republic of Chi…. Hauptthemen laut MEDLINE: Neoplasms, Second Primary, Lymphoma, Non-Hodgkin, Gastrointestinal Neoplasms, Cancer Survivors. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
Therapeutic advances in primary gastrointestinal non‐Hodgkin lymphoma (PGI‐NHL) have improved patient prognosis but also raised concerns regarding long‐term health outcomes. This study assesses patterns of second primary cancers (SPCs) and cause‐specific mortality in PGI‐NHL survivors.
Methods
A total of 7556 six‐month survivors of PGI‐NHL diagnosed between 1975 and 2015 were identified from the SEER database. SPC risks were evaluated using overall and site‐specific standardized incidence ratios (SIRs) and absolute excess risks (AERs) relative to the US general population. Cause‐specific mortality was assessed through proportional death distribution, the Fine–Gray competing risk regression model, standardized mortality ratios (SMRs), and AERs.
Results
During 75,914 person‐years of follow‐up, 1245 patients developed 1412 SPCs (SIR = 1.20, 95% CI = 1.14–1.27). Significantly elevated SIRs were observed for solid tumors (SIR = 1.16, 95% CI = 1.10–1.23) and hematolymphoid malignancies (SIR = 1.82, 95% CI = 1.49–2.19). Survivors with over 20 years of follow‐up faced increased risks of oral cavity and pharyngeal cancers (SIR = 2.76, 95% CI = 1.11–5.69), gastric cancer (SIR = 3.12, 95% CI = 1.15–6.80), pancreatic cancer (SIR = 2.40, 95% CI = 1.10–4.55), and leukemia (SIR = 2.57, 95% CI = 1.17–4.87). The risk of developing SPCs decreased with increasing age at PGI‐NHL diagnosis. Patients receiving combined chemoradiotherapy exhibited the highest overall SPC risk (SIR = 1.32, 95% CI = 1.09–1.58), particularly for gastric cancer (SIR = 8.20, 95% CI = 4.59–13.53) and pancreatic cancer (SIR = 3.15, 95% CI = 1.44–5.98). A total of 4949 deaths occurred (SMR = 1.80, 95% CI = 1.75–1.85), with excess mortality persisting beyond two decades. The cumulative incidence of all‐cause mortality was 28.9% at 5 years, 45.8% at 10 years, and 69.1% at 20 years post‐diagnosis. Non‐cancer causes posed a significant risk, with higher mortality from infections (SMR = 2.48, 95% CI = 2.22–2.76), chronic liver diseases (SMR = 1.72, 95% CI = 1.20–2.38), and benign/in situ neoplasms (SMR = 1.62, 95% CI = 1.05–2.38).
Conclusions
PGI‐NHL survivors face elevated long‐term SPC risk, particularly after chemoradiotherapy and in younger patients. Excess risks for both SPCs and mortality persist beyond two decades, necessitating lifelong, risk‐adapted survivorship care that includes cancer surveillance, infection prevention, and chronic comorbidity management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, People's Republic of China.
- Graduate School, Zhejiang University School of Medicine, Hangzhou, Zhejiang, People's Republic of China.
- Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education) of the Second Affiliated Hospital and Institute of Translational Medicine, Zhejiang University School of Medi…
- Cancer Center of Zhejiang University, Hangzhou, Zhejiang, People's Republic of China.
- School of Basic Medical Sciences and Forensic Medicine, Hangzhou Medical College, Hangzhou, Zhejiang, People's Republic of China.
- Department of Pathology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, People's Republic of China.
ORCID-Profile: Jili Wang, Liangshun You, Feng Zhao
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Wu, J., Yang, J., Ding, Y., Wang, J., Cheng, X., You, L., & Zhao, F. (2025). Second Cancer Incidence and Cause‐Specific Mortality in Primary Gastrointestinal Non‐Hodgkin Lymphoma Survivors: A Population‐Based Cohort Study. Cancer Medicine. https://doi.org/10.1002/cam4.71405
Vancouver
Wu J, Yang J, Ding Y, Wang J, Cheng X, You L, et al. Second Cancer Incidence and Cause‐Specific Mortality in Primary Gastrointestinal Non‐Hodgkin Lymphoma Survivors: A Population‐Based Cohort Study. Cancer Medicine. 2025. doi:10.1002/cam4.71405
BibTeX
@article{Wu2025,
author = {Wu, Jiahe and Yang, Jiangping and Ding, Yuxi and Wang, Jili and Cheng, Xiaofei and You, Liangshun and Zhao, Feng},
title = {Second Cancer Incidence and Cause‐Specific Mortality in Primary Gastrointestinal Non‐Hodgkin Lymphoma Survivors: A Population‐Based Cohort Study},
journal = {Cancer Medicine},
year = {2025},
doi = {10.1002/cam4.71405}
}
EUVIMED